Company Profile
Rosalind Advisors, Inc., often referred to as Rosalind Capital, is an investment firm specializing in life science and biotechnology. The firm operates as an event-driven equity hedge fund, strategically focusing on the life sciences sector to identify and capitalize on market inefficiencies and arbitrage opportunities. Their investment approach is rooted in a deep understanding of both scientific advancements and financial markets.
The firm was established in December 2006 by co-founders Gil Aharon and Steven Salamon. Based in Toronto, Canada, Rosalind Advisors, Inc. has built its foundation on expertise at the intersection of science and finance, aiming to support innovative companies within the biotech landscape.
Rosalind Capital manages several biotech-oriented funds, including Rosalind Capital Partners, Rosalind Master Fund, and Rosalind Offshore Fund. Their portfolio includes notable investments in companies such as Lev Pharmaceuticals, Soligenix, Biofrontera, Kiora Pharmaceuticals, Cellectar Biosciences, and NeurAxis. The firm typically engages in deals ranging from $10 million to $50 million, often investing in startups that are 2-3 years old, indicating a focus on later-stage venture rounds.
The leadership team includes co-founders Gil Aharon, who also serves as a Portfolio Manager, and Steven Salamon. The firm's strategy is driven by their combined expertise in navigating the complexities of the life sciences industry and applying sophisticated financial strategies to generate returns.
News & Signals (0)
No linked news activity found for this company.